All News
Filter News
Found 52 articles
-
ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors
1/7/2021
-- Partnership combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development -- -- ArsenalBio employs a suite of proprietary technologies to encode synthetic biological instructions to overcome solid tumors’ complex defense systems --
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
BioSpace Announces Top New Life Sciences Companies to Watch in 2021
1/6/2021
BioSpace, Inc., the leading life sciences news and careers site, has announced their 25 selections for biopharma's most promising up-and-coming companies in 2021.
-
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
12/7/2020
Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported initial results of a Phase I trial (https://clinicaltrials.gov/ct2/show/NCT03933735) evaluating TNB-383B in Relapsed Refractory Multiple Myeloma (R/R MM) on December 5 at the 62nd American Society of Hematology Annual Conference
-
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
11/23/2020
Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies.
-
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
11/19/2020
Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecifi
-
TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals
11/16/2020
Teneobio, Inc. and its affiliate TeneoFour, Inc. announced a Nature Metabolism publication of a proof of concept study by the Chini Laboratory describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.
-
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
10/21/2020
Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.
-
Bicycle Therapeutics Announces Expansion of Scientific Advisory Board
10/21/2020
Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates
-
Benchling More than Doubles Customer Base for the Second Consecutive Year
12/19/2019
The leading life sciences R&D cloud wins more than 150 new customers in 2019 with continued growth into enterprise market and expansion across new industries
-
ArsenalBio will focus on integrating various technologies, including CRISPR, synthetic biology, and machine learning to discover and develop immunotherapies, initially for oncology.
-
ArsenalBio Launches With $85 Million Series A Financing to Advance New Paradigm to Discover and Develop Immune Cell Therapies
10/17/2019
Aims to create immune cells with significantly larger DNA payloads encoding synthetic biological instructions to overcome solid tumors’ complex defense systems